UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from XXXXXXXX XX, XXXX to XXXXXXXX XX, XXXX Commission File Number: 001-35610 | --- | --- | |------------------------------------------------------------------------ ...

Exhibit 99.1 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks • Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®) • Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024— Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced financial results for the fiscal qu ...

Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®)Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Atossa is a clin ...

Under-the-radar penny stocks can be some of the most rewarding investments on the market. Look at ACADIA Pharmaceuticals (NASDAQ:ACAD), for example. Back in 2011, the biotech was just developing its treatment of Parkinson’s disease psychosis and traded at just 70 cents. By 2015, it was at $51.24.Or, look at Advanced Micro Devices (NASDAQ:AMD). In 2015, it traded at about $1.99. Today, thanks to the artificial intelligence and semiconductor boom, it hit a hit of $214.81.Each had incredible growth stories tha ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer screening starting at age 40. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The updated guidelines recommend women undergo bie ...

SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The expanded research agreement with Weill Cornell will build ...

Proactive新闻团队 - Emily Jarvie在澳大利亚和加拿大从事政治新闻和商业报道[1] - Proactive的新闻团队遍布全球金融和投资中心[2] Proactive团队专注领域 - Proactive团队专注于中小市值市场和蓝筹公司等投资故事[3] - Proactive团队涵盖生物科技、矿业、能源、数字货币和新兴数字技术等领域[4]

SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of si ...

EVANGELINE 临床试验 - Atossa Therapeutics, Inc. 最近宣布了 EVANGELINE 临床试验的阶段2的安全性和有效性数据[1] - EVANGELINE 研究中，(Z)-endoxifen 被评估为一种新辅助治疗，用于对付ER+ / HER2- 乳腺癌的孕前妇女[2] - EVANGELINE 研究的主要目标是确定 (Z)-endoxifen 药物对肿瘤细胞增殖的影响，以及该试验与目前标准治疗 exemestane + goserelin 的区别[4] - 之前的一项阶段2研究数据显示，(Z)-endoxifen 治疗使 Ki-67 降低了65.1%，这在改善ER+乳腺癌患者的长期生存方面具有临床意义[5] - EVANGELINE 研究的 40 毫克药代动力学（PK）试验组的数据显示，在28天的治疗期间，7名妇女中有6名的Ki-67水平在28天内低于10%，并继续接受额外五个月的治疗[6] 疗效数据 - 在 EVANGELINE 研究中接受总共24周治疗的六名患者，磁共振成像（MRI）中心审查显示所有患者的靶病变均减少，其中一个完全缓解，一个部分缓解，四个稳定疾病[7] - 研究数据显示，治疗导致 Ki-67 在28天时降低了63%，在24周时降低了92%。靶病变平均减少了32%在12周和37%在24周的研究中[8] 药物特性 - 40mg EVANGELINE 结果非常积极，因为它证明了 (Z)-endoxifen 可以减少或完全消除肿瘤，并阻止 ER+ 乳腺癌的生长[9] - (Z)-endoxifen 是最有效的选择性雌激素受体调节剂，能够抑制雌激素受体并降解它们[10] - 与传统疗法如他莫昔芬相比，(Z)-endoxifen似乎具有等效或更强的骨骼激素作用，几乎没有子宫内膜增生作用[12]